Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xtant Medical Holdings (XTNT) Non-Current Debt (2016 - 2025)

Xtant Medical Holdings (XTNT) has disclosed Non-Current Debt for 16 consecutive years, with $17.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Debt fell 9.06% to $17.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $17.4 million, a 9.06% decrease, with the full-year FY2024 number at $22.0 million, up 28.37% from a year prior.
  • Non-Current Debt was $17.4 million for Q3 2025 at Xtant Medical Holdings, down from $22.3 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $22.3 million in Q2 2025 to a low of $9.7 million in Q4 2022.
  • A 5-year average of $15.6 million and a median of $15.4 million in 2023 define the central range for Non-Current Debt.
  • Peak YoY movement for Non-Current Debt: plummeted 85.33% in 2021, then surged 77.22% in 2023.
  • Xtant Medical Holdings' Non-Current Debt stood at $11.8 million in 2021, then fell by 17.82% to $9.7 million in 2022, then skyrocketed by 77.22% to $17.2 million in 2023, then rose by 28.37% to $22.0 million in 2024, then decreased by 21.03% to $17.4 million in 2025.
  • Per Business Quant, the three most recent readings for XTNT's Non-Current Debt are $17.4 million (Q3 2025), $22.3 million (Q2 2025), and $22.2 million (Q1 2025).